Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)
Homme Max 99 ans
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)
MAJ Il y a 4 ans
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia
To assess the effect of Tamsulosin OCAS 0.4 mg o.d. compared to placebo on improvement of nocturnal voiding frequency, in subjects with LUTS associated with BPH over 12 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations